Csenge Advisory Group Acquires 6,195 Shares of Medtronic PLC $MDT

Csenge Advisory Group grew its stake in Medtronic PLC (NYSE:MDT) by 100.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,390 shares of the medical technology company’s stock after acquiring an additional 6,195 shares during the period. Csenge Advisory Group’s holdings in Medtronic were worth $1,180,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. Brighton Jones LLC raised its holdings in Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after purchasing an additional 37,265 shares during the last quarter. Sivia Capital Partners LLC grew its position in shares of Medtronic by 9.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after buying an additional 381 shares during the period. Kingstone Capital Partners Texas LLC acquired a new position in Medtronic in the second quarter valued at approximately $7,382,000. Bell Bank acquired a new position in Medtronic in the second quarter valued at approximately $257,000. Finally, Assenagon Asset Management S.A. boosted its stake in Medtronic by 6.7% in the second quarter. Assenagon Asset Management S.A. now owns 63,810 shares of the medical technology company’s stock valued at $5,562,000 after acquiring an additional 4,016 shares during the last quarter. 82.06% of the stock is owned by institutional investors.

Medtronic Stock Performance

Shares of MDT stock opened at $96.82 on Monday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The company has a market capitalization of $124.12 billion, a P/E ratio of 26.10, a price-to-earnings-growth ratio of 2.55 and a beta of 0.71. The company’s 50 day moving average price is $98.99 and its two-hundred day moving average price is $94.93. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter in the prior year, the company earned $1.26 earnings per share. The business’s quarterly revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were given a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. Medtronic’s dividend payout ratio is 76.55%.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on MDT shares. Sanford C. Bernstein increased their price target on Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. The Goldman Sachs Group set a $111.00 target price on Medtronic and gave the company a “neutral” rating in a research note on Wednesday, November 19th. Royal Bank Of Canada raised their target price on Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Morgan Stanley upped their price target on Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a research note on Wednesday, November 19th. Finally, Truist Financial cut their price target on shares of Medtronic from $110.00 to $107.00 and set a “hold” rating on the stock in a research report on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $110.28.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).